Odanacatib (INN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis. It is an inhibitor of cathepsin K, an enzyme...
6 KB (274 words) - 17:27, 28 October 2023
of mouse cathepsin K structural elements that regulate the potency of odanacatib". The Biochemical Journal. 474 (5): 851–864. doi:10.1042/BCJ20160985....
22 KB (2,191 words) - 02:53, 19 August 2024
(INN) Ocuclear Ocufen Ocuflox Ocumycin Ocupress Ocusert Pilo Ocusulf odanacatib (USAN) odronextamab (INN) odulimomab (INN) ofatumumab (INN) oglufanide...
7 KB (366 words) - 22:49, 14 August 2024
and chronic pain. Cathepsin K inhibitors, Relacatib, Balicatib, and Odanacatib, were terminated during clinical trials at phases I, II, and III, respectively...
20 KB (2,372 words) - 09:11, 4 July 2024
inhibitor, odanacatib, in Phase III clinical trials for osteoporosis. In September, 2016, Merck announced they were discontinuing development of odanacatib after...
15 KB (1,713 words) - 02:25, 14 August 2024
actually used in other pharmaceutical applications for the production of Odanacatib, and Sofosbuvir. Zaushitsyna O, Berillo D, Kirsebom H, Mattiasson B (2013)...
18 KB (2,181 words) - 10:09, 30 June 2024